AJP - Heart  AJP: Regulatory, Integrative and Comparative Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (June 9, 2006). doi:10.1152/ajpheart.00061.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/5/H2166    most recent
00061.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jessup, J.
Right arrow Articles by Ferrario, C. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jessup, J.
Right arrow Articles by Ferrario, C. M
Submitted on January 13, 2006
Accepted on June 8, 2006

Effect of Angiotensin II Blockade on a New Congenic Model of Hypertension Derived from Transgenic Ren-2 Rats

Jewel Jessup1, Patricia E. Gallagher1, David B Averill1, K. Bridget Brosnihan1, E. Ann Tallant1, Mark Chappell1, and Carlos M Ferrario1*

1 Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States

* To whom correspondence should be addressed. E-mail: cferrari{at}wfubmc.edu.

The generation of the Lew.Tg(mRen2) congenic hypertensive rat strain, developed through a back-cross of the hypertensive [mRen2]27 transgenic rat with normotensive Lewis rats, provides a new model by which primary hypertension can be studied without the genetic variability found in the original strain. The purpose of this study was to characterize the Lew.Tg(mRen2) rats by dually investigating the effects of type 1 angiotensin II (Ang II) receptor (AT1) blockade and angiotensin converting enzyme (ACE) activity inhibition on the angiotensin-(1-7) [Ang-(1-7)]/angiotensin converting enzyme 2 (ACE2) axis of the renin-angiotensin system (RAS) in thisnew hypertensive model. The control of blood pressure elicited by 12-day administration of either lisinopril (mean difference change = 92 ± 2, p < 0.05) or losartan (mean difference change = 69 ± 2, p < 0.05) was associated with 54% and 33% increases in cardiac ACE2 mRNA and 54% and 43% increases in cardiac ACE mRNA, respectively. Lisinopril induced a 3.1-fold (p < 0.05) increase in renal cortical expression of ACE2 while losartan increased ACE2 mRNA 3.5-fold (p < 0.05). Both treatment regimens increased renal ACE mRNA 2.6-fold (p < 0.05). The two therapies augmented ACE2 protein activity, as well as increased cardiac and renal AT1 receptor mRNAs. ACE inhibition reduced plasma Ang II levels (81%, p < 0.05) and increased plasma Ang-(1-7) (265%, p < 0.05), while losartan had no effect on the peptides. In contrast with what had been shown in normotensive rats, ACE inhibition decreased renal Ang II excretion and transiently decreased Ang-(1-7) excretion, whereas, losartan treatment was associated with a consistent decrease in Ang-(1-7) urinary excretion rates. In response to the treatments, the expression of both renal cortical renin and angiotensinogen mRNAs were significantly augmented. In summary, the paradoxical effects of blockade of Ang II synthesis and activity on urinary excretion rates of the peptides and plasma angiotensins levels suggest that in Lew.Tg(mRen2) congenic rats a failure of compensatory ACE2 and Ang-(1-7)-dependent vasodepressor mechanisms may contribute both to the development and progression of hypertension driven by increased formation of endogenous Ang II.




This article has been cited by other articles:


Home page
Ther Adv Cardiovasc DisHome page
J. A. Jessup, B. M. Westwood, M. C. Chappell, and L. Groban
Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat
Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 245 - 257.
[Abstract] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. J. Soler, M. Ye, J. Wysocki, J. William, J. Lloveras, and D. Batlle
Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan
Am J Physiol Renal Physiol, February 1, 2009; 296(2): F398 - F405.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. E. Gallagher, C. M. Ferrario, and E. A. Tallant
Regulation of ACE2 in cardiac myocytes and fibroblasts
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2373 - H2379.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. D. Pendergrass, N. T. Pirro, B. M. Westwood, C. M. Ferrario, K. B. Brosnihan, and M. C. Chappell
Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H10 - H20.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
I. Hamming, H. van Goor, A. J. Turner, C. A. Rushworth, A. A. Michaud, P. Corvol, and G. Navis
Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats
Exp Physiol, May 1, 2008; 93(5): 631 - 638.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.